এই ওষুধে সাশ্রয় করুন
একই সক্রিয় উপাদানের অন্যান্য ব্র্যান্ড
এই ব্র্যান্ডগুলোতে একই সক্রিয় উপাদান আছে (Apalutamide). একই মাত্রা ও ধরন। বদলানোর আগে আপনার ডাক্তার বা ফার্মাসিস্টের সাথে নিশ্চিত হয়ে নিন।
ইঙ্গিত ও ব্যবহার
Apamid এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
The recommended dose of Apalutamide is 240 mg (four 60 mg tablets) administered orally once daily. Swallow the tablets whole. Apalutamide can be taken with or without food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
পার্শ্বপ্রতিক্রিয়া
The following clinically significant adverse reactions are observed in clinical trial: Endocrine disorders: Hypothyroidism Metabolism and nutrition disorders: hypercholesterolaemia, hypertriglyceridaemia Nervous system disorders: Dysgeusia, seizure Cardiac disorders: ischaemic heart disease Vascular disorders: hot flush, hypertension Gastrointestinal disorders: diarrhea Skin and subcutaneous tissue disorders: skin rash, pruritus Musculoskeletal and connective tissue disorders: fracture, arthralgia, muscle spasm General disorders and administration site conditions: fatigue Investigations: weight decreased Injury, poisoning and procedural complications: fall, fracture
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Seizure: Prostaxen is not recommended in patients with a history of seizures or other predisposing factors including, but not limited to, underlying brain injury, recent stroke (within one year), primary brain tumours or brain metastases. If a seizure develops during treatment with Prostaxen, treatment should be discontinued permanently. In two randomised studies (SPARTAN and TITAN), seizure occurred in 0.4% of patients receiving Prostaxen and in 0.2% of patients treated with placebo. These studies excluded patients with a history of seizure or predisposing factors for seizure.Falls and fractures: Falls and fractures occurred in patients receiving Prostaxen. Patients should be evaluated for fracture and fall risk before starting Prostaxen and should continue to be monitored and managed according to established treatment guidelines and use of bone-targeted agents should be considered.Ischaemic heart disease: Ischaemic heart disease, including events leading to death, occurred in patients treated with Prostaxen. The majority of patients had cardiac risk factors. Patients should be monitored for signs and symptoms of ischaemic heart disease and management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia should be optimised as per standard of care.Concomitant use with other medicinal products: Prostaxen is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products. Concomitant use of Prostaxen with medicinal products that are sensitive substrates of many metabolising enzymes or transporters should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments cannot easily be performed based on monitoring of efficacy or plasma concentrations. Co administration of Prostaxen with warfarin and coumarin-Iike anticoagulants should be avoided. If Prostaxen is co-administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalised Ratio (INR) monitoring should be conducted.Recent cardiovascular disease: Patients with clinically significant cardiovascular disease in the past 6 months including severe/unstabie angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischaemic attacks), or clinically significant ventricular arrhythmias were excluded from the clinical studies. Therefore, the safety of Prostaxen in these patients has not been established. If Prostaxen is prescribed, patients with clinically significant cardiovascular disease should be monitored for risk factors such as hypercholesterolaemia, hypertriglyceridaemia, or other cardio-metabolic disorders. Patients should be treated after initiating Prostaxen for these conditions according to established treatment guidelines.Androgen deprivation therapy may prolong the QT interval: In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval, physicians should assess the benefit-risk ratio including the potential for Torsade de pointes prior to initiating Prostaxen.
নিষেধাজ্ঞা
Hypersensitivity to the active substance Women who are or may become pregnant